Soluble CD30 in normotensive pregnant women with isolated fetal intrauterine growth restriction: a comparison with preeclamptic women

Laskowska, Marzena; Laskowska, Katarzyna; Oleszczuk, Jan

doi:10.1016/j.jri.2010.05.004

Cited by 2 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reports on the patterns of membrane-bound CD30 ligand and its soluble form in serum (sCD30L) in patients with ovarian cancer are sparse and most of them deal with the biological functions of CD30 [6], its associations with pathologies of the lymphatic [7] and gastrointestinal [8] systems, and its role in some disorders during pregnancy [9]. Elevated levels of sCD30L in serum have been observed in viral infections, as well as in autoimmune and atopic diseases.…”

Section: Discussionmentioning

confidence: 99%

“…[7] found elevated sCD30L levels in serum which preceded by 6–10 years the diagnosis of NHL, concluding their report that protracted stimulation of B cells is responsible for the formation of this tumor and that sCD30L is a strong predictor of NHL. Serum concentrations of sCD30L have been studied in gravida [9, 21] and were found to be elevated in comparison with non-gravida. No correlation was noted between gestation time and sCD30L level.…”

Section: Discussionmentioning

confidence: 99%

“…No correlation was noted between gestation time and sCD30L level. Intrauterine growth restriction and pre-eclampsia are accompanied by lower serum sCD30L concentrations than in healthy gravida [9, 21]. Gestational pyelonephritis augments sCD30L concentration in serum regardless of the etiologic factor [21].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of serum levels of sCD30L ligand in patients with ovarian cancer in terms of selected clinico-pathological factors

Chudecka‐Głaz¹,

Rzepka-Górska²

2012

View full text Add to dashboard Cite

Aim of the studyThe CD30L ligand is a membrane-associated glycoprotein expressed by activated CD4+Th cells, macrophages, dendritic cells, and B lymphocytes. It binds to the CD30 receptor carried on activated and helper Th cells, inducing the immune response and apoptosis. The aim of this retrospective study was to determine the level of sCD30L in the serum of patients at diagnosis of ovarian cancer and at relapse and to assess the potential association of this ligand with selected clinico-pathologic factors.Material and methodsWe studied 69 patients with ovarian cancer allocated to two groups: A – ovarian cancer at diagnosis, B – relapse of ovarian cancer and active growth of the tumor.ResultsWe found high levels of sCD30L in ovarian cancer patients. Levels at relapse (21.48 ng/ml) were significantly higher than at diagnosis (11.81 ng/ml). Poor response to first-line chemotherapy was accompanied by higher levels of sCD30L and by several other findings: resistance to platinum analogs was common, neoadjuvant chemotherapy was needed, relapse and death during two-year follow-up were frequent.ConclusionsOur present study might initially suggest that elevated concentration of sCD30L can be an important finding prognosticating a poor prognosis and is associated with platinum resistant and refractory cases of ovarian cancer. However, studies are needed on larger groups of patients.

show abstract